Watch out, Pfizer: Affinivax lands $226M in funding to advance Prevnar 13 rival as well as the rest of its pipeline
Affinivax CEO Steven Brugger hit the clinic a couple years ago with an unconventional take on a pneumococcal vaccine designed to dethrone Pfizer’s Prevnar 13. And now that the candidate’s ready for Phase III, Brugger has reeled in a $226 million mega-round to see it through.
The Series C comes several months after a $120 million raise, with Viking Global Investors, Bain and Ziff Capital Partners participating in both rounds. It’s quite the accomplishment for a company that launched with $4 million in seed funding from the Gates Foundation back in 2014.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.